HUTCHMED DRC

Price & Volume

Stats

52W Range	$12.84-$21.92
Market Cap	$2.6B
Shares Short	357,656

Financials

Revenue (12 Mos)	$630.2M
Revenue Growth (YoY)	6.4%
Gross Profit (12 Mos)	$69.2M
Diluted EPS	$0.20

News

Yahoo Finance • 13 days ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Yahoo Finance • 14 days ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Yahoo Finance • 9 months ago

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

Yahoo Finance • last year

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

About

CEO	Dr. Wei-Guo Su B.Sc., Ph.D.
CFO	Mr. Chig Fung Cheng BEc, CA
Address	Cheung Kong Center, Hong Kong, Hong Kong
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Full-Time Employees	1,811